Table 1.
Baseline characteristics of the study population according to sex-specific C-reactive protein quartiles.
| Sex-Specific Quartiles
|
P | ||||
|---|---|---|---|---|---|
| 1stQ (n=199) | 2nd Q (n=196) | 3rd Q (n=196) | 4th Q (n=194) | ||
| CRP*, mg/L | 0.44 | 1.19 | 2.48 | 6.50 | <0.001 |
| Age, yr | 64±10 | 64±9 | 65±9 | 63±8 | 0.34 |
| Female, n(%) | 97 (49) | 97 (50) | 96 (49) | 96 (50) | 0.998 |
| Ethnicity, n(%) | |||||
| Non-Hispanic white | 68 (34) | 61 (31) | 63 (32) | 49 (25) | 0.26 |
| Chinese American | 68 (34) | 33 (17) | 26 (13) | 12 (6) | <0.001 |
| African American | 32 (16) | 50 (26) | 51 (26) | 67 (35) | 0.001 |
| Hispanic | 31 (16) | 52 (27) | 56 (29) | 66 (34) | <0.001 |
| Current smoking, n(%) | 7 (4) | 16 (8) | 24 (12) | 32 (27) | <0.001 |
| Hypertension, n(%) | 74 (37) | 85 (43) | 93 (47) | 115 (59) | <0.001 |
| Diabetes, n(%) | 17 (9) | 25 (13) | 20 (10) | 33 (17) | 0.06 |
| Body mass index, kg/m2 | 24.9±3.6 | 27.8±4.4 | 28.1±4.3 | 30.2±4.9 | <0.001 |
| GFR, ml/min | 82.5±15.8 | 80.5±18.9 | 79.9±17.3 | 82.0±18.1 | 0.44 |
| Statin use, n(%) | 47 (24) | 38 (19) | 31 (16) | 25 (13) | 0.04 |
| Aspirin use, n(%) | 55 (28) | 50 (26) | 40 (20) | 44 (23) | 0.35 |
| LV end-diastolic volume, ml | 122.5±33.0 | 122.8±32.1 | 122.3±29.9 | 125.2±29.8 | 0.81 |
| LV ejection fraction, % | 69.0±7.3 | 69.1±6.6 | 69.6±7.5 | 69.3±8.2 | 0.83 |
| LV mass index, g/m2 | 77.3±19.1 | 77.5±15.6 | 76.9±13.7 | 80.1±16.9 | 0.25 |
| LV mass, g | 138.1±42.8 | 143.2±37.2 | 143.1±34.6 | 153.1±39.1 | 0.002 |
| CAC score >0 | 102 (51) | 96 (49) | 106 (54) | 107 (55) | 0.61 |
*
Median;
_CRP (mg/L) quartiles for women: first, 0.35–0.90; second, 1.36 −2.08; third, 2.88–4.31; fourth, 6.52–11.68. for men; first, 0.30–0.51; second, 0.75–1.06; third, 1.47–2.22; fourth, 3.35–6.49, CRP, C-reactive protein; GFR, glomerular filtration rate; LV, left ventricular; CAC, coronary artery calcium by CT